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Abstract
Docetaxel (Dtx) chemotherapy is the optional treatment in patients with hormone-refractory metastatic prostate
cancer, and Dtx-loaded polymeric nanoparticles (NPs) have the potential to induce durable clinical responses.
However, alternative formulations are needed to overcome the serious side effects, also due to the adjuvant used,
and to improve the clinical efficacy of the drug.
In the present study, two novel biodegradable block-copolymers, poly(lactide-co-caprolactone) (PLA-PCL) and poly
(lactide-co-caprolactone-co-glycolide) (PLGA-PCL), were explored for the formulation of Dtx-loaded NPs and
compared with PLA- and PLGA-NPs. The nanosystems were prepared by an original nanoprecipitation method,
using Pluronic F-127 as surfactant agent, and were characterized in terms of morphology, size distribution,
encapsulation efficiency, crystalline structure, and in vitro release. To evaluate the potential anticancer efficacy of a
nanoparticulate system, in vitro cytotoxicity studies on human prostate cancer cell line (PC3) were carried out. NPs
were found to be of spherical shape with an average diameter in the range of 100 to 200 nm and a unimodal
particle size distribution. Dtx was incorporated into the PLGA-PCL NPs with higher (p < 0.05) encapsulation
efficiency than that of other polymers. Differential scanning calorimetry suggested that Dtx was molecularly
dispersed in the polymeric matrices. In vitro drug release study showed that release profiles of Dtx varied on the
bases of characteristics of polymers used for formulation. PLA-PCL and PLGA-PCL drug loaded NPs shared an
overlapping release profiles, and are able to release about 90% of drug within 6 h, when compared with PLA- and
PLGA-NPs. Moreover, cytotoxicity studies demonstrated advantages of the Dtx-loaded PLGA-PCL NPs over pure Dtx
in both time- and concentration-dependent manner. In particular, an increase of 20% of PC3 growth inhibition was
determined by PLGA-PCL NPs with respect to free drug after 72 h incubation and at all tested Dtx concentration.
In summary, PLGA-PCL copolymer may be considered as an attractive and promising polymeric material for the
formulation of Dtx NPs as delivery system for prostate cancer treatment, and can also be pursued as a validated
system in a more large context.
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Prostate cancer (PCa) is the most common male malig-
nancy and the second leading cause of cancer death in
Western industrialized countries [1]. The PCa progres-
sion does not only mean distant metastases but also
development of hormone independence of its cells [2].
Docetaxel (Dtx)-based regimen is recommended as
optional treatment in patients with hormone-refractory
metastatic PCa, showing effective on locally advanced
PCa and increasing overall survival [3]. Despite the
recently reported promising outcome of Dtx, this drug
is associated with systemic toxicity that limits the dose
and duration of therapy, particularly in elderly patients.
Adverse effects of Dtx treatment include hypersensitivity
reactions, bone marrow suppression, cutaneous reac-
tions, fluid retention, peripheral neuropathy, alopecia,
cardiac disorders, and tiredness [4]. Moreover, to facili-
tate its clinical use, the Dtx poor water solubility
requires a specific solvent system, such as ethanol/
Tween 80 solution, which causes hypersensitivity reac-
tion, reduced uptake by tumor tissue and increased
exposure to other body compartments [5].
Therefore, alternative Dtx formulations are needed
and nanoparticles (NPs)-based drug delivery systems are
of special interest in addressing the major side effects of
anticancer drug.
Recently, a number of polymers have been investigated
for formulating biodegradable Dtx-loaded NPs for can-
cer chemotherapy. The most widely used class of bio-
compatible and biodegradable polymers, approved by
Food and Drug Administration (FDA), is that of alipha-
tic polyesters, including poly(lactic acid) (PLA), poly(gly-
colic acid) (PLGA), and their copolymers [6].
However, these polymers are characterized by a high
hydrophobicity and slow degradation rate that can
represent in some cases a disadvantage for their use as
drug carriers [7].
In the family of polyesters, polycaprolactone (PCL)
shows an excellent biocompatibility and rapid degrad-
ability, good miscibility with a variety of polymers and
great permeability, which make it a suitable candidate
for drug carrier [8].
The methods for the preparation of NPs from the pre-
formed polymers include nanoprecipitation, emulsifica-
tion/solvent evaporation, emulsification/solvent
diffusion, and salting out [9]. As for the nanoprecipita-
tion, the particle formation is based on precipitation and
subsequent solidification of the polymer at the interface
between a solvent and a non-solvent [10]. Usually, sur-
factants or stabilizers are included in the process to
modify the size and the surface properties, and to
ensure the stability of the NP dispersion [9]. The most
popular stabilizer for the production of PLGA-based
NPs is poly(vinyl alcohol) (PVA). However, it has been
found that residual PVA, which is very difficult to
remove from the particles’ surface, causes relatively
lower cellular uptake, thus resulting not satisfactorily
biocompatible for the human body [11]. Therefore,
other surfactants could be considered as valuable alter-
natives to PVA. Poloxamer, a block copolymer of poly
(ethylene oxide)-poly(propylene oxide)-poly(ethylene
oxide), commercially known as Pluronic, is another pro-
mising surface active agent approved by FDA for clinical
use [12]. Additionally, several evidence demonstrated
that poloxamers interact with multidrug-resistant
tumors, resulting in a drastic sensitization of these
tumors with respect to various anticancer agents [13,14].
The present work is aimed at investigating the influ-
ence of two previously unexplored biodegradable block-
copolymers, such as poly(D,L-lactide-co-caprolactone)
(PLA-PCL) and poly(L-lactide-co-caprolactone-co-
glycolide) (PLGA-PCL), on the physicochemical and
pharmaceutical properties of novel Dtx-loaded NPs,
using PLA- and PLGA-NPs as comparison. The
designed nanosystems were obtained by a modified
nanoprecipitation technique, using Pluronic F-127
instead of PVA as stabilizing agent. The NPs were char-
acterized in terms of morphology, encapsulation effi-
ciency and crystalline structure, and in vitro release
kinetics. Moreover, the antiproliferative efficacy of the
most promising nanoparticulate prototype was assessed
by in vitro cytotoxicity assay toward a human prostate
cancer cell line (PC3).
Materials and methods
Materials
Poly(D,L-lactide) (PLA) (inherent viscosity 0.55 to
0.75 dl/g in chloroform), poly(D,L-lactide-co-glycolide)
(PLGA) (lactide:glycolide 50:50 molar ratio, inherent
viscosity 0.55 to 0.75 dl/g in hexafluoroisopropanol)
with esters end groups were purchased from Lactel
Absorbable Polymers (Pelham, AL, USA). Poly(L-lactide-
co-caprolactone-co-glycolide) (PLGA-PCL) (L-lactide:
glycolide:caprolactone 70:10:20 molar ratio, inherent
viscosity 1.30 dl/g, in chloroform) was obtained from
Sigma-Aldrich (Steinheim, Germany). Poly(L-lactide-co-
caprolactone) (PLA-PCL) (lactide:caprolactone 70:30
molar ratio) was kindly provided from Purac Biomater-
ials (Gorinchen, Netherlands). Pluronic
® F-127 was
obtained from Sigma-Aldrich (Steinheim, Germany).
Docetaxel (purity 99%) was supplied by ChemieTek
(Indianapolis, IN, USA). All other chemicals were analy-
tical grade and were used without further purification.
Formulation of nanoparticles
Drug-loaded NPs were prepared by a novel nanoprecipi-
tation method. Briefly, about 100 mg of polymer and
drug (1%, w/w) were dissolved in 6 ml of acetonitrile.
Sanna et al. Nanoscale Research Letters 2011, 6:260
http://www.nanoscalereslett.com/content/6/1/260
Page 2 of 9The organic solution was then added dropwise under
stirring to an aqueous solution of Pluronic F-127 (1% w/
v, 30 ml). The milky colloidal suspension was evapo-
rated at room temperature to remove the organic sol-
vent. The suspension was centrifuged at 13,000 rpm for
10 min to separate the NPs from the unencapsulated
drug and residual Pluronic. The pellet was washed thrice
with ultrapure water. Drug-free NPs were produced in a
similar manner. The obtained NP suspension was used
immediately for assay or lyophilized for storage at -50°C.
Characterization of NPs
Particle size and size distribution
Mean diameter and size distribution of the NPs were
measured by photon correlation spectroscopy with
Coulter N4 plus particle size analyzer (Beckman Coulter,
Fullerton, CA, USA). The samples were diluted with
deionized water and sonicated for 5 min before mea-
surement. Each analysis was carried out in triplicate.
Surface morphology
The morphological examination of NPs was performed
by scanning electron microscopy (SEM) (model DSM
962; Carl Zeiss Inc., Oberkochen, German). A drop of
NPs suspension was placed on a glass cover slide and
dried under vacuum for 12 h. After that, the slides were
mounted on aluminum stub and the samples were then
analyzed at 20 kV acceleration voltage after gold sput-
tering, under an argon atmosphere.
Encapsulation efficiency and yield of production
To determine the drug loading, an aliquot of NPs
(1.0 mg) was dissolved in 0.25 ml of acetonitrile/water
(50/50, v/v) solution. Samples were centrifuged and the
drug content in the supernatant was analyzed by HPLC
using the method previously reported [15]. The equip-
ment consisted of an HPLC system including an auto-
sampler and a diode array detector (HP 1200, Agilent
Technologies, Santa Clara, CA, USA). The chromato-
graphic separation was performed at room temperature
using a Jupiter C18 column (250 mm × 2.0 mm, 5 μm
pore size, Phenomenex) with a flow rate of 0.2 ml/min.
Twenty microlitres of samples or calibration standards
were injected into the column and eluted with a solu-
tion of acetonitrile/water solution (50/50, v/v). Detection
was carried out by monitoring the absorbance signals at
227 nm. The elution period was 25 min and the reten-
tion time of Dtx was about 9 min. HPLC was calibrated
with standard solutions of 5 to 50 μg/ml of Dtx (correla-
tion coefficient of R
2 = 0.9999).
The drug encapsulation efficiency (EE%) was calcu-
lated as the ratio between the amount of Dtx encapsu-
lated in NPs and the weight of drug used for NP
preparation.
The lyophilized NPs from each formulation were
weighed and the respective percentage yield of
production was calculated as the ratio between the
amount of NPs weight obtained and the total weight of
solid materials used for the preparations.
Differential scanning calorimetry (DSC)
DSC scans of empty and drug-loaded NPs were per-
formed on a DSC Q100 V 9.0 calorimeter (TA Instru-
m e n t ,N e wC a s t l e ,U S A ) .I n d i u mw a su s e dt oc a l i b r a t e
the instrument. The thermograms of samples were
obtained at a scanning rate of 10°C/min in 30 to 200°C
temperature range and performed under an Ar purge
(50 ml/min). The thermal measurements were carried
out on pure Dtx, on freeze-dried empty and drug-loaded
NPs.
In vitro drug release
For the in vitro release studies, about 10 mg of Dtx-NPs
were suspended in 2.0 ml of release medium (phosphate
buffer solution of pH 7.4 containing 0.1% w/v Tween
80). The tubes were then incubated at 37°C and shaken
horizontally at 200 rpm (Thermomixer HLC BioTech,
Bovenden, Germany). At predetermined time intervals,
the tubes were centrifuged at 13,000 rpm for 10 min
and 1.0 ml aliquots of medium were taken from super-
natant and replaced with fresh solution. The collected
samples were extracted with 0.2 ml dichloromethane,
evaporated by nitrogen stream, and reconstituted in
100 μl mobile phase.
The concentration of Dtx released from the NPs was
determined by HPLC assay as described above and cor-
rected for the dilution due to the addition of fresh
medium.
In vitro cytotoxicity assay
With respect to particle size, encapsulation efficiency,
and yield of production results, the PLGA-PCL Dtx-
loaded NPs were selected for the in vitro cytotoxicity
studies. A batch of empty PLGA-PCL NPs was used as
comparison.
Cancer cell viability of the drug-loaded NPs was evalu-
ated by MTT assay. Hundred microliters of PC3 cells
were seeded in 96-well plates (Costar, IL, USA) at the
density of 5,000 viable cells/well and allowed to adhere
for 24 h.
The cells were incubated with free Dtx, Dtx-loaded
NP suspension at 0.05, 0.5, 5.0 μg/ml equivalent Dtx
concentrations, and empty NPs with the same NP con-
centrations, for 24, 48, and 72 h, respectively. The
selected concentrations were in the range which corre-
sponds to plasma levels of the drug achievable in
humans [16]. At designated time intervals, the medium
was removed, and the wells were washed twice with
PBS. Ten microliters of 3-(4,5-dimethyl-thiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) solution were
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another 1 to 4 h. The absorbance was measured at
560 nm using a microplate reader. Cell viability was cal-
culated by the following equation:
Cell viability(%) =( A b s sample/Abscontrol) × 100,
where Abssample is the absorbance of the cells incu-
bated with the NP suspension, and Abscontrol is the
absorbance of the cells incubated with the culture med-
ium only (positive control). All experiments were
repeated thrice.
Statistical methodology
The data are expressed as mean ± standard deviation
(S.D.). The significance of differences was assessed by
one-way analysis of variance (ANOVA) (Origin
®,v e r -
sion 7.0 SR0, OriginLab Corporation, Northampton,
MA, USA) and considered significant when p < 0.05.
Results and discussion
Characterization of NPs
Size, drug entrapment efficiency, and yields of production
The nanoprecipitation method described here appeared
to be a suitable technique to formulate Dtx-loaded NPs
based on PLA and PLGA and their poly-caprolactone
copolymers. The preparation was carried out by using a
polymer concentration in organic phase of 3.3 mg/ml
and a solvent:Pluronic
® F-127 solution ratio of 1:5. Acet-
onitrile was selected as organic phase for the capability to
solubilize the polymers and drug and its good water mis-
cibility, that allows a fine polymer dispersion into water.
Moreover, although the most commonly used PVA emul-
sifier can make uniform particles with small size, it has been
recently demonstrated that it can form an interconnected
network with the PLGA polymer at the interface that
would compromise the good redispersibility of NPs [11].
Additionally, the residual PVA associated with the surface
of NPs would influence their physical properties and cellu-
lar uptake. Therefore, due to the above reasons, PVA was
conveniently replaced with Pluronic in the current study.
The prepared NPs were characterized in terms of par-
ticle size and size distribution, morphology, encapsula-
tion efficiency, and yield of production. The effect of
different polymers on the characteristics of NPs is sum-
marized in Table 1.
All NP batches showed a particle diameter ranging
f r o m1 0 0t o2 0 0n m ,s u i t a b l et oo b t a i na ne f f e c t i v e
intracellular uptake [17]. NPs formulated with PLA-PCL
polymer showed a significantly larger (p < 0.05) mean
diameter (195 nm) than that of the PLGA- and PLGA-
PCL-Dtx-loaded NPs (107 and 115 nm, respectively). As
depicted in Figure 1, in all cases, the NP dispersions
exhibit a unimodal particle size distribution, as also con-
firmed by the obtained low polydispersity indexes (PDI
< 0.31), typical of monodispersed systems. This suggests
that the presence of Pluronic F127 can promote the for-
mation of very homogeneous NP dispersions.
As far as the drug entrapment efficiency (EE) is con-
cerned, from drug content analysis no significant differ-
ences were found for the batches based on PLA and
PLGA polymers (38 and 35%, respectively). On the
other hand, relevant differences are obtained for NPs
formulated with both copolymers containing PCL. The
PLGA-PCL NPs exhibited significantly (p < 0.05) higher
drug encapsulation efficiency (47%) compared with
other formulations.
This finding can be ascribed to the presence of three
polymers, PLA, PLGA, and PCL, which are able to generate
a polymer network characterized by a greatly irregular and
disordered crystalline structure, which may consequently
promote the accommodation of the drug molecules.
Conversely, the lower percentages of encapsulation
efficiency and NP yield obtained with PLA-PCL copoly-
mer might be explained with a partial and fast precipita-
tion of polymer that occurs after addition of organic
phase to surfactant solution. Yields of production ranged
between 52 and 84%, with the highest values for NPs
based on PLGA-PCL copolymers.
Furthermore, the size and particle size distribution of
unloaded NPs were similar to the corresponding loaded
batches, thus indicating tha tt h ep r e s e n c eo ft h ed r u g
did not influence these characteristics (data not shown).
Surface morphology
The morphology of NPs was investigated by SEM analy-
sis. As displayed in Figure 2, all batches of NPs showed
a spherical shape with a smooth surface, without any
particle aggregation.
The partial fusion detected in some NP samples takes
place during the analysis, where many NPs congregate
together. Due to presence of the drug, no difference in
the morphological properties of NPs drug was observed
due to the presence of the drug.
Differential scanning calorimetry (DSC)
The physical state of Dtx inside the NPs was character-
ized by analysis of the DSC curves. The pure drug shows
ac h a r a c t e r i s t i ce n d o t h e r m ic peak that corresponds to
Table 1 The effect of the different type of polymers on
characteristic of NPs
Polymeric NPs Size (nm) PDI EE (%) YP (%)
PLA 146.3 ± 23.5 0.198 ± 0.03 37.8 ± 3.0 51.9 ± 1.4
PLGA 106.7 ± 13.5 0.108 ± 0.04 35.2 ± 2.6 68.2 ± 2.7
PLA-PCL 194.8 ± 31.2 0.308 ± 0.08 19.7 ± 1.4 36.8 ± 1.6
PLGA-PCL 114.8 ± 15.4 0.258 ± 0.07 47.2 ± 3.8 83.9 ± 3.3
Data are shown as mean ± S.D., obtained from three formulations. PDI,
polydispersity index; EE, encapsulation efficiency; YP, yield of production.
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The comparison between DSC thermograms of drug with
unloaded and loaded NPs formulated with different poly-
mers showed similar behaviors.
In all cases, the DSC scans revealed that Dtx melting
peak totally disappeared in the calorimetric curve of
loaded NPs, thus evidencing the absence of crystalline
drug in the samples. These results suggested that the
nanoencapsulation inhibited the crystallization of Dtx
during NPs formation. Thus, it can be assumed that Dtx
was present in the NPs either in an amorphous or disor-
dered crystalline phase or in the solid solution state [6].
Meanwhile, the loaded systems exhibited the same
endothermic events (at 58°C for PLA, 52°C for PLGA,
54°C for PLA-PCL, and 50 and 113°C for PLGA-PCL) of
the corresponding unloaded NPs, referring to melting
temperature (Tm) of polymers (Figure 3a to 3d), sug-
gesting that the nanoencapsulation procedure did not
affect the polymer structure.
In vitro drug release
The cumulative percentages of Dtx released from NPs
based on different polymers as a function of time are
reported in Figure 4. All formulations are characterized
by similar release profiles, but the release rate is strongly
affected by the properties of the polymer matrix. In parti-
cular, PLA-based NPs are characterized by the slower
release (only about 60% of Dtx is released within 6 h)
that can be attributed to the stronger hydrophobic inter-
action between hydrophobic domain of PLA and drug.
Due to the presence of the hydrophilic glycolide units
into the PLA polymer (50:50 molar ratio), in the case of
NPs formulated with PLGA a completed dissolution of
Dtx is achieved within the first 2 hof the test. In fact, the
higher hydrophilicity of copolymer improved the water
permeability into NPs with a more rapid drug diffusion
as well as a faster degradation of the polymer [8]. As for
PCL copolymers, the diffusion rate of drug from PLA-
PCL NPs is higher at the first 2 h and levelled off after 3
h of the test, thus resulting almost superimposed to those
of PLGA-PCL formulations. These results can be related
to the similar composition of PLA-PCL and PLGA-PCL
copolymers containing a lactide:caprolactone 70:30 and
lactide:glycolide:caprolactone 70:10:20 molar ratio,
respectively. Moreover, with respect to PLGA, a signifi-
cant retard on dissolution rate of Dtx from PLGA-PCL
Figure 1 Particles size distribution of PLA-Dtx (a), PLGA-Dtx (b), PLA-PCL-Dtx, (c) and PLGA-PCL-Dtx-loaded NPs (d).
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observed in the case of PLA-PCL copolymer compared
to PLA-NPs. Furthermore, with respect to PLA homopo-
lymer, the more hydrophilic block of caprolactone of
PLA-PCL copolymer-based NPs leads to a significant
improvement of Dtx released (85%, during the 6 h).
A complete release of Dtx is obtained for all samples
after 24 h of the test.
In order to investigate the kinetic modeling of drug
release from NPs, the dissolution profiles were fitted to
zero order (Q = k0·t); first order (ln (100 - Q)=l nQ0 -
k1·t), Higuchi (Q = kH·t
1/2), and Korsmeyer-Peppas models
[18].
Table 2 shows the correlation coefficient (r
2)u s e da s
an indicator of the best fitting of the models considered
for different Dtx-NPs batches. The r
2 values for first
order kinetics of different polymeric NPs (ranging
between 0.8830 and 0.9921) were greater than that of
Zero order and corresponded to that of the Higuchi’s
square root of time (ranged between 0.8182 and 0.9813).
Besides, to understand the drug release mechanism, the
first 60% drug release data was fitted to Korsmeyer-Pep-
pas exponential model Mt/M∞ = Kt
n ,w h e r eMt/M∞ is
fraction of drug released after time ‘t’ and ‘K’ is kinetic
constant and ‘n’ is release exponent, which characterizes
the different drug release mechanism [19]. Based on var-
ious mathematical models, the magnitude of the release
exponent ‘n’ indicates the release mechanism (Fickian
diffusion, case II transport, or anomalous transport).
The limits considered were n ≤ 0.43 (for a classical Fickian
diffusion-controlled drug release) and n =0 . 8 5( i n d i c a t e sa
Figure 2 Scanning electron microscopic images of PLA-Dtx (a),
PLGA-Dtx (b), PLA-PCL-Dtx (c), and PLGA-PCL-Dtx-loaded NPs
(d).
Figure 3 DSC thermograms of pure Dtx compared with unloaded and loaded PLA (a), PLGA (b), PLA-PCL (c), and PLGA-PCL NPs (d).
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order release). Values of n between 0.43 and 0.85 can be
regarded as an indicator of both phenomena (drug diffu-
sion in the hydrated matrix and the polymer relaxation)
usually called anomalous transport [19]. In all formula-
tions, n values ranged from 0.5141 to 0.7842, suggesting
an anomalous or non-Fickian diffusion, which is related to
combination of both diffusion of the drug and dissolution
of the polymer.
In vitro cytotoxicity assay
The in vitro cytotoxicity of Dtx both as free drug and
loaded into PLGA-PCL NPs, at the same drug equiva-
lent concentration of 0.05, 0.5, and 5.0 μg/ml, was evalu-
ated by the MTT assay using PC3 as model prostate
cancer cell line. Untreated PC3 cells as well as cells trea-
ted with empty PLGA-PCL NPs, with the same polymer
content of that of the drug-loaded nanosystems, were
used as comparison.
Figure 5 shows the viability of PC3 cancer cells, cul-
tured with unloaded PLGA-PCL NPs, and Dtx-loaded
PLGA-PCL NPs, after incubation for 24 h (a), 48 (b),
and 72 h (c), in comparison with that of pure drug at
0.05, 0.5, and 5.0 μg/ml equivalent Dtx concentrations.
Figure 4 In vitro release profiles of Dtx-loaded PLA, PLGA,
PLA-PCL, and PLGA-PCL NPs.
Table 2 Correlation coefficients (r
2) and release exponent
(n) of kinetic data analysis of Dtx release from different
polymeric NPs
Polymeric
NPs
Zero order
r
2
First order
r
2
Higuchi
r
2
Koresmeyer-
Peppas
r
2 n
PLA 0.8875 0.9481 0.9813 0.9962 0.5141
PLGA 0.6295 0.8830 0.8182 0.9942 0.6706
PLA-PCL 0.7997 0.9503 0.9280 0.9956 0.7166
PLGA-PCL 0.8797 0.9921 0.9747 0.9988 0.7842
Figure 5 Viability of PC3 cells cultured with drug-free
nanoparticles (NP), docetaxel-loaded PLGA-PCL NPs (NP-Dtx)
after 24 h (a), 48 h (b) and 72 h (c), in comparison with that of
pure drug (Dtx) at the same dose (n =3 ) . Asterisks, significantly
different from control; circle, significantly different from each other.
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detected, drug-free NPs appeared nearly non-toxic to PC3
cells, even at a high NP concentration, thus confirming
the good biocompatibility of PLGA-PCL copolymer [20].
On the whole, the results clearly demonstrated that
Dtx formulated in PLGA-PCL NPs resulted more effec-
tive against cancer cells than free Dtx. Both the dose
exposure and the incubation time played a major role in
the cell toxicity of Dtx.
In particular, after 24 h incubation, the PC3 cell viabi-
lity was decreased to about 65, 55, and 40% for PLGA-
PCL NPs at 0.05, 0.5, and 5.0 μg/ml drug concentration,
respectively, corresponding to an increase in cytotoxicity
of 25% (p < 0.05) compared with that of free Dtx.
After 48 h incubation, the cytotoxicity was increased
about 55, 60, and 70% for the PLGA-PCL-Dtx NPs and
25, 35, and 45% for free drug, respectively.
The more marked inhibition of cell growth was
obtained for longer incubation period (72 h); at all
tested Dtx concentration, PLGA-PCL NPs determined a
significant (p < 0.05) increased of PC3 growth inhibition
(about 20%) with respect to free drug. With an approxi-
mately 85% cell viability reduction, the strongest cyto-
toxic effect was achieved with NPs at 5.0 μg/ml Dtx
concentration.
This finding is related with the mechanism of action
of Dtx, which requires cell division to operate. In fact,
for longer incubation periods, a larger number of cells
enter G2 and M cell cycle phases, where Dtx selectively
works [21].
According to literature data, the higher cytotoxicity of
the drug formulated into NPs can be attributed to the
combination of different but not exclusive mechanisms.
In fact, the NPs were adsorbed on the cell surface lead-
ing to an increase in drug concentration near the cell
membrane, thus generating a concentration gradient
that promotes the drug influx into the cell [16]. Besides,
while part of free Dtx molecules, transported into the
cytoplasm by a passive diffusion, were transported out
by P-glycoprotein (P-gp) pumps, NPs are taken up by
cells through an endocytosis pathway, thus resulting in a
higher cellular uptake of the entrapped drug [22],
thereby enabling them to escape from the effect of P-gp
pumps. Moreover, intracellular delivery of Dtx NPs
allows a drug accumulation near the site of action [23].
Conclusions
In this work, poly(lactide-co-caprolactone) and poly(lactide-
co-caprolactone-co-glycolide) copolymers were successfully
employed for the first time for the nanoencapsulation of
Dtx, by using a modified nanoprecipitation method.
Among the investigated copolymers, PLGA-PCL resulted
more effective than PLA-PCL-NPs to achieve NPs with
small size, uniform distribution, and higher encapsulation
efficiency. The in vitro studies proved an increased antipro-
liferative efficacy of PLGA-PCL-Dtx NPs compared with
free Dtx, in a dose- and time-dependent manner, against
PC3 cells.
In conclusion, the PLGA-PCL copolymer can be con-
sidered as alternative and promising biocompatible poly-
mer to be used on development of NP-based drug
delivery system for cancer chemotherapy.
Acknowledgements
The research activities presented were done within the frame of ‘Progetto
Cluster - Sviluppo ed Utilizzo di Nanodevices’, funded by Sardinian
Technology Park - Porto Conte Ricerche, Italy. A grant from Banco di
Sardegna Foundation to GP also partially supported this work. The authors
thank the Company Purac Biomaterials (Gorinchen, Netherlands) for
providing PLA-PCL polymer.
Author details
1Porto Conte Ricerche, Località Tramariglio, Alghero, Sassari 07041, Italy
2Department of Biomedical Sciences, Centre of Excellence for Biotechnology
Development and Biodiversity Research, University of Sassari, Viale San Pietro
43/B, Sassari 07100, Italy
3Istituto di Scienze delle Produzioni Alimentari
(ISPA), CNR, Via dei Mille 48, Sassari 07100, Italy
4Department of Chemistry
and local INSTM unit, University of Sassari, Via Vienna 2, Sassari 07100, Italy
5Dipartimento di Scienze del Farmaco, University of Sassari, Via Muroni 23/A,
Sassari 07100, Italy
Authors’ contributions
VS conceived of the study, participated in its design and coordination,
carried the nanoformulation experiments, and wrote the manuscript. AMR
participated in the design of the study, carried the HPLC experiments and
contributed to data interpretation. AMP and AC performed the biological
experiments, and GP analyzed and organized the results. SM carried out the
SEM analysis. AM and VA performed the DSC measurements and organized
data analysis. SU has been involved in revising the manuscript critically. MS
participated in the experimental setup development as well as discussions
and data analysis, and helped in writing the manuscript. All authors read
and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 16 December 2010 Accepted: 28 March 2011
Published: 28 March 2011
References
1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics,
2009. CA Cancer J Clin 2009, 59:225-249.
2. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA,
Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED:
Docetaxel and estramustine compared with mitoxantrone and prednisone
for advanced refractory prostate cancer. N Engl J Med 2004, 351:1513-1520.
3. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S,
Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA, TAX 327
Investigators: Docetaxel plus prednisone or mitoxantrone plus
prednisone for advanced prostate cancer. N Engl J Med 2004,
351:1502-1152.
4. Petrylak DP: The treatment of hormone-refractory prostate cancer:
docetaxel and beyond. Rev Urol 2006, 8:S48-S55.
5. Lee E, Kim H, Lee IH, Jon S: In vivo antitumor effects of chitosan-
conjugated docetaxel after oral administration. J Control Release 2009,
140:79-85.
6. Musumeci T, Ventura C, Giannone I, Ruozi B, Montenegro L, Pignatello R,
Puglisi G: PLA/PLGA nanoparticles for sustained release of docetaxel. Int J
Pharm 2006, 325:172-179.
7. Zhang Z, Feng SS: Nanoparticles of poly(lactide)/vitamin E TPGS
copolymer for cancer chemotherapy: synthesis, formulation,
characterization and in vitro drug release. Biomaterials 2006, 27:262-270.
Sanna et al. Nanoscale Research Letters 2011, 6:260
http://www.nanoscalereslett.com/content/6/1/260
Page 8 of 98. Zhang H, Cui W, Bei J, Wang S: Preparation of poly(lactide-co-glycolide-
co-caprolactone) nanoparticles and their degradation behaviour in
aqueous solution. Polym Degrad Stab 2006, 91:1929-1936.
9. Hans ML, Lowman AM: Biodegradable nanoparticles for drug delivery
and targeting. Curr Opin Solid State Mater Sci 2002, 6:319-327.
10. Pinto Reis C, Neufeld RJ, Ribeiro AJ, Veiga F: Nanoencapsulation I.
Methods for preparation of drug-loaded polymeric nanoparticles.
Nanomedicine 2006, 2:8-21.
11. Sahoo SK, Panyam J, Prabha S, Labhasetwar V: Residual polyvinyl alcohol
associated with poly(D,L-lactide-co-glycolide) nanoparticles affects their
physical properties and cellular uptake. J Control Release 2002, 82:105-114.
12. Khattak SF, Bhatia SR, Roberts SC: Pluronic F127 as a cell encapsulation
material: utilization of membrane-stabilizing agents. Tissue Eng 2005,
11:974-983.
13. Moghimi SM, Hunter AC: Poloxamers and poloxamines in nanoparticle
engineering and experimental medicine. Trends Biotechnol 2000,
18:412-420.
14. Yan F, Zhang C, Zheng Y, Mei L, Tang L, Song C, Sun H, Huang L: The
effect of poloxamer 188 on nanoparticle morphology, size, cancer cell
uptake, and cytotoxicity. Nanomedicine 2010, 6:170-178.
15. Immordino ML, Brusa P, Arpicco S, Stella B, Dosio F, Cattel L: Preparation,
characterization, cytotoxicity and pharmacokinetics of liposomes
containing docetaxel. J Control Release 2003, 91:417-429.
16. Fonseca C, Simoes S, Gaspar R: Paclitaxel-loaded PLGA nanoparticles:
preparation, physicochemical characterization and in vitro anti-tumoral
activity. J Control Release 2002, 83:273-286.
17. Cho K, Wang X, Nie S, Chen Z, Shin DM: Therapeutic nanoparticles for
drug delivery in cancer. Clin Cancer Res 2008, 14:1310-1316.
18. Mehta AK, Yadav KS, Sawant KK: Nimodipine loaded PLGA nanoparticles:
formulation optimization using factorial design, characterization and in
vitro evaluation. Curr Drug Deliv 2007, 4:185-193.
19. Korsmeyer RW, Gurney R, Doelker E, Buri P, Peppas NA: Mechanism of
solute release from porous hydrophilic polymer. J Pharm Sci 1983,
15:25-35.
20. Jeong SI, Kim BS, Kang SW, Kwon JH, Lee YM, Kim SH, Kim YH: In vivo
biocompatibilty and degradation behavior of elastic poly(L-lactide-co-
epsilon-caprolactone) scaffolds. Biomaterials 2004, 25:5939-5946.
21. Luo Y, Ling Y, Guo W, Pang J, Liu W, Fang Y, Wen X, Wei K, Gao X:
Docetaxel loaded oleic acid-coated hydroxyapatite nanoparticles
enhance the docetaxel-induced apoptosis through activation of
caspase-2 in androgen independent prostate cancer cells. J Control
Release 2010, 147:278-288.
22. Panyam J, Labhasetwar V: Dynamics of endocytosis and exocytosis of
poly(D,L-lactide-co-glycolide) nanoparticles in vascular smooth muscle
cells. Pharm Res 2003, 20:212-220.
23. Yoo HS, Park TG: Folate-receptor-targeted delivery of doxorubicin nano-
aggregates stabilized by doxorubicin-PEG-folate conjugate. J Control
Release 2004, 100:247-256.
doi:10.1186/1556-276X-6-260
Cite this article as: Sanna et al.: Novel docetaxel-loaded nanoparticles
based on poly(lactide-co-caprolactone) and poly(lactide-co-glycolide-co-
caprolactone) for prostate cancer treatment: formulation,
characterization, and cytotoxicity studies. Nanoscale Research Letters 2011
6:260.
Submit your manuscript to a 
journal and beneﬁ  t from:
7 Convenient online submission
7 Rigorous peer review
7 Immediate publication on acceptance
7 Open access: articles freely available online
7 High visibility within the ﬁ  eld
7 Retaining the copyright to your article
    Submit your next manuscript at 7 springeropen.com
Sanna et al. Nanoscale Research Letters 2011, 6:260
http://www.nanoscalereslett.com/content/6/1/260
Page 9 of 9